Calmark establishes cooperation with Nordic Match on Chinese expansion
Today, Calmark Sweden AB has resolved to initiate a cooperation with Nordic Match, a boutique M&A and Strategy Advisor for Sino-Nordic transactions. The cooperation covers the Chinese market entry for Calmark and the planning of a joint venture. The project will commence during summer and the expected project duration is approximately 18 months. Calmark thus advances the launch in China by about two years.
The vision of Nordic Match is to support Nordic companies and Chinese investors in their search for value-creating opportunities between the regions. Headquartered in Shanghai, China, the company has successfully assisted a number of Nordic companies with their market launches, expansions, mergers, acquisitions and joint ventures. With the right investors, this type of corporate structure can accelerate the establishment and increase the value of the company.
"The purpose of this cooperation is to establish subsidiaries in Hong Kong and mainland China, initiate the registration process for the products, and recruit skilled staff," says Anna Söderlund, CEO of Calmark. "We are further making plans for a joint venture together with Chinese investors regarding the mainland China subsidiary, Calmark China. Nordic Match has strong relations and an extensive network of investors in China; we consider it a valuable asset."
"We are delighted to enter into cooperation with Calmark, and we believe that this will be a successful project," says Markus Dahlström, Partner at Nordic Match. "China has a vast demand for innovative medical technology products and point-of-care diagnostics is a rapidly growing segment in the country. Calmark is an exciting company with important products that are likely to attract the interest of Chinese investors and business partners."
This information is information that Calmark Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 18:45 CEST on 16 July 2020.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a reader and single-use products. The first three tests are being launched in 2020. WHO expects 1.5 billion children to be born worldwide prior to 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer decision-making support, which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: